Stay updated on Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial
Sign up to get notified when there's something new on the Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial page.

Latest updates to the Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check22 days agoChange DetectedA sitewide notice announces an NIH terminology transition, saying federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference0.4%

- Check29 days agoChange DetectedThe ClinicalTrials.gov site footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check36 days agoChange DetectedThe ClinicalTrials.gov page footer shows a newer site revision, changing from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check56 days agoChange DetectedA new page revision label v3.7.0 has been added to the study history, replacing the previous revision v3.6.6.SummaryDifference0.1%

- Check64 days agoChange DetectedOn 2026-09-10 the record shows that results have been posted and new sections for Adverse Events, Baseline Characteristics, Contacts/Locations, and Study Status were added (with 2026-08-18 represented as version 53). The prior 2026-05-05 'Results Submitted' entry was removed.SummaryDifference0.4%

Stay in the know with updates to Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capivasertib+Abiraterone in PTEN-deficient Prostate Clinical Trial page.